Monopar Therapeutics Inc. (MNPR)
USD 37.49
(7.45%)
USD 37.49
(7.45%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | 8.83 Million | 10.53 Million | 9.12 Million | 6.5 Million | 4.32 Million | 3.4 Million |
| Selling, General and Administrative Expenses | 3.23 Million | 2.94 Million | 2.63 Million | 2.44 Million | 2.35 Million | 1.62 Million |
| Research and Development Expenses | 5.6 Million | 7.59 Million | 6.49 Million | 4.06 Million | 1.96 Million | 1.77 Million |
| Other Expenses | - | - | - | - | - | - |
| Cost and Expenses | 8.83 Million | 10.53 Million | 9.12 Million | 6.5 Million | 4.32 Million | 3.4 Million |
| Operating Income | -8.83 Million | -10.53 Million | -9.12 Million | -6.5 Million | -4.32 Million | -3.4 Million |
| Interest Expense | - | - | - | - | - | 103.21 Thousand |
| Income Tax Expense | - | -21.23 Thousand | -24.02 Thousand | -81.9 Thousand | -98.88 Thousand | -71.61 Thousand |
| Earnings before Tax | -8.4 Million | -10.51 Million | -9.1 Million | -6.3 Million | -4.22 Million | -3.29 Million |
| Net Income | -8.4 Million | -10.49 Million | -9.07 Million | -6.22 Million | -4.12 Million | -3.22 Million |
| Earnings Per Share Basic | -0.58 | -0.83 | -0.73 | -0.57 | -0.39 | -0.31 |
| Earnings Per Share Diluted | -0.58 | -0.83 | -0.73 | -0.57 | -0.39 | -0.31 |
| Weighted Average Shares Outstanding | 14.51 Million | 12.71 Million | 12.47 Million | 10.95 Million | 10.58 Million | 10.42 Million |
| Weighted Average Shares Outstanding (Diluted) | 14.51 Million | 12.71 Million | 12.47 Million | 10.95 Million | 10.58 Million | 10.42 Million |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | 429.03 Thousand | - | - | - | - | - |
| Earnings Before Tax Margin | - | - | - | - | - | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | 1.78 Million | 1.72 Million | 8.83 Million | 1.91 Million | 2.06 Million | 2.32 Million |
| Selling, General and Administrative Expenses | 657.8 Thousand | 757.28 Thousand | - | 876.39 Thousand | 749.47 Thousand | 733.49 Thousand |
| Research and Development Expenses | 1.13 Million | 966.11 Thousand | - | 1.03 Million | 1.31 Million | 1.59 Million |
| Other Expenses | -657.8 Thousand | - | - | - | - | - |
| Cost and Expenses | 1.78 Million | 1.72 Million | 8.83 Million | 1.91 Million | 2.06 Million | 2.32 Million |
| Operating Income | -1.78 Million | -1.72 Million | -8.83 Million | -1.91 Million | -2.06 Million | -2.32 Million |
| Interest Expense | - | - | - | 90.48 Thousand | - | - |
| Income Tax Expense | -1.78 Million | -1.72 Million | -8831.23 | -1911.99 | 112.14 Million | 128.08 Million |
| Earnings before Tax | -1.71 Million | -1.64 Million | -8.4 Million | -1.81 Million | -1.95 Million | -2.19 Million |
| Net Income | -1.71 Million | -1.64 Million | -8.4 Million | -1.81 Million | -1.95 Million | -2.19 Million |
| Earnings Per Share Basic | -0.49 | -0.10 | - | -0.12 | -0.14 | -0.16 |
| Earnings Per Share Diluted | -0.49 | -0.10 | - | -0.12 | -0.14 | -0.16 |
| Weighted Average Shares Outstanding | 3.5 Million | 15.97 Million | 2.76 Million | 14.9 Million | 14.11 Million | 13.42 Million |
| Weighted Average Shares Outstanding (Diluted) | 3.5 Million | 15.97 Million | 2.76 Million | 14.9 Million | 14.11 Million | 13.42 Million |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | -1.78 Million | -1.72 Million | - | -1.91 Million | -2.06 Million | -2.32 Million |
| Earnings Before Tax Margin | - | - | - | - | - | - |
CCNEP
TMUS
6634
3497
0KU1
6944